Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 60.9% in April

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRXGet Rating) saw a large increase in short interest in April. As of April 30th, there was short interest totalling 209,200 shares, an increase of 60.9% from the April 15th total of 130,000 shares. Based on an average daily volume of 316,100 shares, the short-interest ratio is currently 0.7 days. Approximately 1.8% of the company’s stock are short sold.

A number of institutional investors and hedge funds have recently modified their holdings of KPRX. BlackRock Inc. bought a new position in Kiora Pharmaceuticals during the 4th quarter worth $32,000. Renaissance Technologies LLC bought a new position in Kiora Pharmaceuticals during the 1st quarter worth $58,000. Finally, Geode Capital Management LLC bought a new position in Kiora Pharmaceuticals during the 4th quarter worth $791,000. Hedge funds and other institutional investors own 29.70% of the company’s stock.

Shares of NASDAQ KPRX traded up $0.08 during trading on Friday, reaching $0.45. The stock had a trading volume of 237,026 shares, compared to its average volume of 118,070. The firm has a market capitalization of $5.67 million, a PE ratio of -0.29 and a beta of 0.94. The stock has a 50 day simple moving average of $0.58. Kiora Pharmaceuticals has a one year low of $0.35 and a one year high of $6.43.

A number of equities research analysts have recently weighed in on the company. Maxim Group assumed coverage on Kiora Pharmaceuticals in a report on Wednesday, January 19th. They issued a “buy” rating and a $2.50 price target for the company. HC Wainwright lowered their price target on Kiora Pharmaceuticals from $5.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, April 19th.

Kiora Pharmaceuticals Company Profile (Get Rating)

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.

Further Reading

Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with's FREE daily email newsletter.